Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
NCT04235101
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
SYD985 + Niraparib
Sponsor
Byondis B.V.